The role of stem cell transplantation in multiple myeloma - PubMed

Review

The role of stem cell transplantation in multiple myeloma

Jean-Luc Harousseau et al. Blood Rev. 2002 Dec.

Abstract

High-dose therapy with autologous stem cell transplantation (ASCT) has been extensively used in the past 15 years in multiple myeloma. The IFM 90 trial has shown that autologous bone marrow transplantation (BMT) is superior to conventional chemotherapy in terms of response rate, event free survival, overall survival. Several other randomized studies confirm that ASCT yields superior complete remission and event free survival rates. However, the benefit for overall survival is not always significant because some patients may receive high-dose therapy at the time of relapse. While ASCT appears to be the treatment of choice for younger patients, a number of questions have been addressed in the past few years (optimal conditioning regimen, best source of stem cells, impact of tandem autotransplants, role of maintenance therapy, results of transplantation in patients over 65 years of age or with renal failure). These issues are addressed in this review. Analysis of large cohorts of patients indicate that a low beta2 microglobulin level and the absence of chromosome 13 abnormalities are associated with a better outcome. However patients with a high-beta2 microglobulin level and chromosome 13 abnormalities, the prognosis is poor even after tandem transplantations. Allogeneic BMT is offered to a minority of younger patients with an HLA identical sibling. Initial series have shown a high-toxic death rate and no survival advantage compared to ASCT. However, allogeneic BMT is possibly the only curative therapy. Reports of CR achieved after infusion of donor lymphoid cells in patients relapsing after allogeneic BMT support the concept of graft versus myeloma effect. Therefore, the objectives of current studies is to reduce transplant related mortality by using earlier BMT, better selection of patients, better graft-versus host prophylaxis or non myeloablative conditioning regimens.

Similar articles

• [Intensive treatment of multiple myeloma].

  Harousseau JL. Harousseau JL. Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Bull Acad Natl Med. 2003. PMID: 14556449 Review. French.

• Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.

  Björkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Bladé J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G. Björkstrand BB, et al. Blood. 1996 Dec 15;88(12):4711-8. Blood. 1996. PMID: 8977265

• Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

  Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Kuruvilla J, et al. Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. doi: 10.1016/j.bbmt.2007.04.006. Epub 2007 May 29. Biol Blood Marrow Transplant. 2007. PMID: 17640596 Clinical Trial.

• The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma.

  Cavo M, Benni M, Gozzetti A, Tura S. Cavo M, et al. Baillieres Clin Haematol. 1995 Dec;8(4):795-813. doi: 10.1016/s0950-3536(05)80260-4. Baillieres Clin Haematol. 1995. PMID: 8845573 Review.

• The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.

  Kyle RA. Kyle RA. Ann Oncol. 2000;11 Suppl 1:55-8. Ann Oncol. 2000. PMID: 10707780 Review.

Cited by

• A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

  Rifkin RM, Greenspan A, Schwerkoske JF, Mandanas RA, Stephenson JJ, Kannarkat GT, Zhan F, Boehm KA, Asmar L, Beveridge R. Rifkin RM, et al. Invest New Drugs. 2012 Apr;30(2):714-22. doi: 10.1007/s10637-010-9556-6. Epub 2010 Oct 12. Invest New Drugs. 2012. PMID: 20938715 Clinical Trial.

• α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

  Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M. Teiluf K, et al. Oncotarget. 2015 Mar 10;6(7):4692-703. doi: 10.18632/oncotarget.2986. Oncotarget. 2015. PMID: 25576914 Free PMC article.

• Role of autologous stem cell transplantation in multiple myeloma.

  Kumar S. Kumar S. Curr Hematol Malig Rep. 2007 May;2(2):121-7. doi: 10.1007/s11899-007-0017-z. Curr Hematol Malig Rep. 2007. PMID: 20425360 Review.

• Multiple myeloma.

  Rajkumar SV. Rajkumar SV. Curr Probl Cancer. 2009 Jan-Feb;33(1):7-64. doi: 10.1016/j.currproblcancer.2009.01.001. Curr Probl Cancer. 2009. PMID: 19254626 Free PMC article. Review. No abstract available.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal